Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Medazepam→

Medazepam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2898-12-6
Molecular formula
C16H15ClN2
Molecular weight
270.75 g/mol
Drug class
Benzodiazepine anxiolyticpositive allosteric modulator of GABAA receptors
Mechanism of action
Enhances GABA-mediated inhibition through positive allosteric modulation of GABAA receptor complexes at the benzodiazepine binding site, increasing chloride-channel opening and neuronal hyperpolarisation.
Indications / reported uses
  • Short-term symptomatic treatment of anxiety in countries where medazepam remains authorised; availability is limited and use is subject to benzodiazepine dependence, sedation and withdrawal precautions

Sources: NLM MeSH — Medazepam · PubMed — Medazepam benzodiazepine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Medazepam Environmental Risk Assessment (ERA) (the Medazepam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.